Ponatinib

Results: 34



#Item
11HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ICLUSIG safely and effectively. See full prescribing information for ICLUSIG. ICLUSIG® (ponatinib) tablets for oral

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ICLUSIG safely and effectively. See full prescribing information for ICLUSIG. ICLUSIG® (ponatinib) tablets for oral

Add to Reading List

Source URL: www.ariad.com

Language: English - Date: 2014-10-07 13:49:25
12HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ICLUSIG safely and effectively. See full prescribing information for ICLUSIG. ICLUSIG® (ponatinib) tablets for oral

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ICLUSIG safely and effectively. See full prescribing information for ICLUSIG. ICLUSIG® (ponatinib) tablets for oral

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2014-07-25 12:30:45
13Ottobre[removed]Elenchi dei prodotti medicinali per le malattie rare in Europa*

Ottobre[removed]Elenchi dei prodotti medicinali per le malattie rare in Europa*

Add to Reading List

Source URL: www.orpha.net

Language: English - Date: 2014-11-03 09:45:01
14Division: Pharmacy Services Subject: Prior Authorization Criteria Original Development Date: Original Effective Date:

Division: Pharmacy Services Subject: Prior Authorization Criteria Original Development Date: Original Effective Date:

Add to Reading List

Source URL: ahca.myflorida.com

Language: English - Date: 2014-03-05 14:03:05
15Division: Pharmacy Services Subject: Prior Authorization Criteria Original Development Date: Original Effective Date:

Division: Pharmacy Services Subject: Prior Authorization Criteria Original Development Date: Original Effective Date:

Add to Reading List

Source URL: www.fdhc.state.fl.us

Language: English - Date: 2014-03-05 14:03:05
16Division: Pharmacy Services Subject: Prior Authorization Criteria Original Development Date: Original Effective Date:

Division: Pharmacy Services Subject: Prior Authorization Criteria Original Development Date: Original Effective Date:

Add to Reading List

Source URL: www.ahca.myflorida.com

Language: English - Date: 2014-03-05 14:03:05
17CML, ALL, and B‐Cell Lymphomas: Understanding Professional Practice Gaps and Educational Needs among Hematologists and Medical Oncologists in the United States

CML, ALL, and B‐Cell Lymphomas: Understanding Professional Practice Gaps and Educational Needs among Hematologists and Medical Oncologists in the United States

Add to Reading List

Source URL: www.annenberg.net

Language: English - Date: 2013-08-29 18:07:02
18ASCO ANSWER S C H RO N I C M Y E LO I D L E U K E M I A Illustration by Robert Morreale/Visual Explanations, LLC. © 2004 American Society of Clinical Oncology. WHAT IS CHRONIC MYELOID LEUKEMIA? Chronic myeloid leukemia

ASCO ANSWER S C H RO N I C M Y E LO I D L E U K E M I A Illustration by Robert Morreale/Visual Explanations, LLC. © 2004 American Society of Clinical Oncology. WHAT IS CHRONIC MYELOID LEUKEMIA? Chronic myeloid leukemia

Add to Reading List

Source URL: www.cancer.net

Language: English - Date: 2013-11-01 16:15:03
19PRESSEMITTEILUNG 50. Erstattungsbetrag erfolgreich verhandelt Berlin, [removed]: Mit Ponatinib (Handelsname Iclusig ) vom Hersteller ARIAD ® Pharmaceuticals liegt der 50. Erstattungsbetrag vor, der nach den Kriterien

PRESSEMITTEILUNG 50. Erstattungsbetrag erfolgreich verhandelt Berlin, [removed]: Mit Ponatinib (Handelsname Iclusig ) vom Hersteller ARIAD ® Pharmaceuticals liegt der 50. Erstattungsbetrag vor, der nach den Kriterien

Add to Reading List

Source URL: www.gkv-spitzenverband.de

Language: German - Date: 2014-08-29 19:00:33
    20CDER New Molecular Entity (NME) & New BLA Calendar Year Approvals As of December 31, 2012 Selection Criteria: User Response: Start Date: [removed]

    CDER New Molecular Entity (NME) & New BLA Calendar Year Approvals As of December 31, 2012 Selection Criteria: User Response: Start Date: [removed]

    Add to Reading List

    Source URL: www.fda.gov

    Language: English